![]() ![]() Swanson willing to take the huge risk of leaving lucrative plastic surgery positions with no way back? And is the way they launched PolarityTE a new superior model for launching a biotech start-up? PolarityTE was one of only four life science firms that went public immediately without an Initial Public Offering (IPO). Of the last 50 biotech startups, only about 14% launched without funding from VC firms (and only 4% without either VC or Angel investors). As a result, most inventors turn their technologies over to VC firms to take them forward - and consequently they typically end up with less than 5% equity in the start-up. But the risks of leaving a medical institution are so high - because there is no way back - that most life science inventors don’t take the risk. This is startling because in virtually 100% of high tech start-ups that go public, the founder-inventor does work for the company and is viewed as a valuable resource (can you imagine Amazon without Jeff Bezos? Tesla without Elon Musk? Facebook without Zuckerberg?). Indeed, in 92% of the last 100 life science start-ups to go public, the MD inventor of the flagship product didn’t work for the company. Lough and Swanson are taking a huge gamble because the culture in the medical community is that you don’t leave to try a start-up and then come back if it doesn’t work. (Nasdaq:COOL) in hopes that a merger between a 31-year-old failing gaming company and their own revolutionary technology would provide the field of medicine with the ability to regenerate new tissue - skin, bone, muscle, etc. But on December 1 st of 2016, Lough and Swanson were catapulted instantaneously from coveted Plastic Surgery resident positions to the CEO and COO of Majesco Entertainment Co. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |